AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05164692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% NaCl physiological saline
Description: Nasal-spraying 0.9% NaCl physiological saline is prepared by extracting 5 mL from 0.9% NaCl intravenous infusion 500 mL PP bottle (B.Braun, Germany, product declaration No. VD-32732-19), and then pouring it into the same opaque plastic spraying 10 mL-bottle that is used for LiveSpo Navax.
Study NCT03530683 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maplirpacept (PF-07901801)
Description: maplirpacept (PF-07901801) will be administered by intravenous infusion at ranging doses, as determined from sequential dosing cohorts.
Study NCT02031055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102 tablets
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
Study NCT03121261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levobupivacaine
Description: Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
Study NCT00488540 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Suppository
Study NCT00488540 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Suppository
Study NCT03121261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine
Description: Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
Study NCT03121261 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clonidine
Description: Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
Study NCT03121261 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine
Description: Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
Study NCT02794428 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine
Description: Eflornithine\*, 2 tablets, Oral, Daily for 18 months
Study NCT02794428 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Eflornithine placebo
Description: Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
Study NCT01190488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: End-of-Life / Advanced Care Decision Aid
Description: Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
Study NCT01190488 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator
Description: TAU
Study NCT00513123 — intervention group
Intervention type: PROCEDURE
Intervention: Colposcopy
Description: As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
Study NCT03504527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: double combinations
Description: inhaled formotero(4.5ug,bid) and tiotropium bromide(18μg,qd)
Study NCT02796365 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
Study NCT03155269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fortified Beverage Powder
Description: The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
Study NCT03155269 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Non fortified beverage Powder
Description: The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
Study NCT02139969 — intervention group
Intervention type: DEVICE
Intervention: GreenLight XPS Laser System
Study NCT00466440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: enzastaurin
Description: 1125 mg loading dose, then 500 mg po QD until disease progression, toxicity, or maximum 3 years
Study NCT04443426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral 3-hydroxybutyrate salts
Description: Comercially available 3-hydroxybutyrate salts with 36 grams of 3-OHB salts three times daily.
Study NCT04443426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Carbohydrate Placebo
Description: Comercially available carbohydrate sports drink. The placebo dose is isocaloric to the 3-hydroxy butyrate dose.
Study NCT04443426 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone Monoester
Description: Commercially available ketone monoester in a dosage isocaloric to 3-OHB salts.
Study NCT02162381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylphenidate
Description: a single dose of methylphenidate 10 mg to be taken orally in the morning
Study NCT02162381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: guidance
Description: subjects will be given an explanation and advice about how to perform well in visual field testing
Study NCT02162381 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: guidance
Description: subjects will be given an explanation and advice about how to perform well in visual field testing
Study NCT03952377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SX600
Description: Transforaminal Epidural Injection
Study NCT03952377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Transforaminal Epidural Injection
Study NCT01224769 — intervention group
Intervention type: DRUG
Intervention: bendamustine +/- rituximab
Study NCT03699956 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RRx-001 + eLOOP Device
Description: RRx-001 is a small molecule anticancer drug which is mixed with patient's own blood using the eLOOP device
Study NCT03699956 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/carboplatin plus etoposide
Description: Standard of care platinum doublet chemotherapy
Study NCT03699956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin/carboplatin plus etoposide
Description: Standard of care platinum doublet chemotherapy
Study NCT01856296 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Study NCT01001286 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questscope Non-Formal Education
Description: Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators).
Study NCT01001286 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questscope Non-Formal Education
Description: Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.~Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators).
Study NCT01188759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voriconazole
Description: For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks.
Study NCT01188759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anidulafungin
Description: Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).~Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole.
Study NCT01188759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Voriconazole
Description: For Children aged 2-11 years and adolescents aged 12-14 years weighing \<50 kg:~Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.~For adolescents aged 12-17 years, excluding 12-14-year-olds weighing \<50kg:~Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.~Voriconazole therapy is to be given for 6-12 weeks.
Study NCT02619565 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: blood samples
Description: blood samples at Day 0 and also if there is an evolution of the disease
Study NCT00466440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Loading dose, then po QD until unblinding
Study NCT00466440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 75 mg/m\^2 IV, every 21 days, six 21-day cycles, maximum 10 cycles
Study NCT05246631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone injection
Description: Group A consisted of patients given 5 mg intravenous dexamethasone after induction.
Study NCT05246631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol Injection
Description: Group B consisted of patients given 1 mg intravenous haloperidol one hour before the surgery ended
Study NCT03207607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control snack
Description: Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
Study NCT03207607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Maltodextrin snack
Description: Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
Study NCT03207607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whey protein snack
Description: Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
Study NCT03207607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oat snack
Description: Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
Study NCT03207607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coconut oil snack
Description: Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
Study NCT03207607 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Snack skipping
Description: no snack
Study NCT03291249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Foralumab
Description: Anti CD3 mAb
Study NCT03291249 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo oral solution
Study NCT03291249 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Omeprazole 20mg
Description: Omeprazole is a proton pump inhibitor used to neutralize stomach PH
Study NCT03291249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole 20mg
Description: Omeprazole is a proton pump inhibitor used to neutralize stomach PH
Study NCT02608827 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resperate®-InterCure Ltda
Description: The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
Study NCT02608827 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Music group (GC)
Description: The patients in this arm will hear slow music - Music group (GC).
Study NCT04897724 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dental composite
Description: clinical performance of composite restorations used for posterior teeth in patients with Amelogenesis Imperfecta
Study NCT03487146 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hemoperfusion(HP)
Description: These patients were computer-matched into two groups, involving 100 patients with absolute HD vs. 100 cases with HD+HP.HP was performed 1-2 times/per 2 weeks, and each session lasted for two hours.Self-reported sleep disturbance was evaluated before and after observational time (two-year period), which lasted at least 7 hours based on the recommendations presented by National Institute of Health (NIH). Sleep efficiency (%) was calculated as the ratio of sleep duration to total time in bed, and was multiplied by 100.
Study NCT02317796 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MLR-1023
Description: Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
Study NCT02317796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MLR-1023
Description: Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
Study NCT03718221 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care FIT Screening Strategy
Description: Patients in usual care neighborhoods will receive FIT kits randomly throughout the year.
Study NCT03718221 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GeoMail FIT Screening Strategy
Description: Patients in treated neighborhoods will receive kits at the same time.
Study NCT02611076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stop Smoking for Good Intervention in Spanish (SS-SP)
Description: Assessments will occur at six-month intervals, through 24 months.
Study NCT02611076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care (UC)
Description: Assessments will occur at six-month intervals, through 24 months.
Study NCT02006810 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Induction of endothelial function variations
Study NCT02006810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Induction of endothelial function variations
Study NCT00714025 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 10mg, daily, PO
Study NCT01370291 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: active Risperidone and active rTMS
Description: active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
Study NCT01370291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active rTMS and sham Risperidone
Description: active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
Study NCT01370291 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: sham rTMS and active Risperidone
Description: active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
Study NCT00466440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: 5 mg po BID, six 21-day cycles
Study NCT03463291 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: * T1 weighted image.~* Fast spin-echoT2 weighted image.~* Short inversion recovery (STIR).~* T1-fat suppressed images.~* Diffusion weighted sequences with different b values 0-1000 s/mm2 with qualitative assessments by the different b values as well as quantitative assessment by measurement of the ADC values.
Study NCT03627572 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: Not applicable (no intervention)
Study NCT04843956 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasound-guided biopsy
Description: Capillary with suction (puncture with gradual withdrawal of the stylet, applying dry suction with a 10 ml air vacuum syringe after removing the stylet)~Capillary without suction (puncture with removal of the stylet gradually, without suction after removing the stylet)~wet suction (Prior to puncture, the stylet is removed from the needle and irrigated with 1-2 ml saline solution to replace the air column with liquid, then the solid lesion is punctured and suction is placed with a 10 ml vacuum syringe of air)
Study NCT00360035 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obatoclax mesylate (GX15-070MS)
Description: 60 mg q2wks
Study NCT02121808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIPPV
Description: Ventilation: non-invasive positive pressure ventilation (NIPPV)~Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)
Study NCT02009488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 100 mg
Description: One 100 mg capsule taken orally (by mouth) once daily
Study NCT02009488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin, 300 mg
Description: One 300 mg capsule taken orally (by mouth) once daily
Study NCT02121808 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tidal volume
Description: Tidal volume spontaneous ventilation, no assistance.
Study NCT02009488 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo capsule (inactive medication) once daily.
Study NCT03275324 — intervention group
Intervention type: DEVICE
Intervention: Capnostream20p
Description: Observational study of patients connected to the Capnostream20p monitor.
Study NCT03678311 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Positive Airway Pressure (CPAP)
Description: If diagnosed with Long QT Syndrome and have Sleep Apnea index >5 pauses per hour then given CPAP to wear for approximately 3 months.
Study NCT03088527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD140
Description: RAD140 will be supplied as formulated drug-in-capsules for oral administration.
Study NCT02135055 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood sample collection
Description: Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
Study NCT04274101 — intervention group
Intervention type: OTHER
Intervention: Clinical Manifestations
Description: Clinical manifestations in patients treated with Nifurtimox and Benznidazole
Study NCT02135055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
Study NCT02985294 — intervention group
Intervention type: OTHER
Intervention: Multiple Excitability Measures of peripheral nerves
Description: The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and 'threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
Study NCT02135055 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.
Study NCT02135055 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sedation interruption
Description: Sedation interruption is performed at 8 am every morning.
Study NCT04274101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Serologic response
Description: Serologic response in patients treated with Nifurtimox and Benznidazole
Study NCT04274101 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Direct method
Description: Direct method tests in patients treated with Nifurtimox and Benznidazole